The role of methotrexate as combination therapy with etanercept in rheumatoid arthritis: Retrospective analysis of a local registry

Journal of International Medical Research

Volumn 44, Issue 1_suppl, 2016, Pages 113-118

  Becciolini, Andrea ^a   Biggioggero, Martina ^a   Favalli, Ennio Giulio ^b  

^a UNIVERSITY OF MILAN   (Italy)

^b ISTITUTO ORTOPEDICO GAETANO PINI   (Italy)

Author keywords

Combination therapy; etanercept; methotrexate; rheumatoid arthritis

Indexed keywords

ETANERCEPT; METHOTREXATE;

ADULT; ARTICLE; COMPARATIVE EFFECTIVENESS; DRUG DOSE COMPARISON; DRUG MEGADOSE; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; SIMPLIFIED DISEASE ACTIVITY INDEX;

EID: 84988953715     PISSN: 03000605     EISSN: 14732300     Source Type: Journal    
DOI: 10.1177/0300060515593261     Document Type: Article

References (12)

1. Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment of rheumatoid arthritis in the biologic era: still an “anchor” drug? Autoimmun Rev 2014; 13: 1102–1108.
2. Smolen JS, Landewé R, Breedveld FC. EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update. Ann Rheum Dis 2014; 73: 492–509.
3. Singh JA, Furst DE, Bharat A. 2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2012; 64: 625–639.
4. Klareskog L, van der Heijde D, de Jager JP. Therapeutic effect of the combination of etanercept and methotrexate compared with each treatment alone in patients with rheumatoid arthritis: double-blind randomized controlled trial. Lancet 2004; 363: 675–681.
5. Breedveld FC, Weisman MH, Kavanaugh AF. The PREMIER study: a multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previous methotrexate treatment. Arthritis Rheum 2006; 54: 26–37.
6. Burmester GR, Kivitz AJ, Kupper H. Efficacy and safety of ascending methotrexate dose in combination with adalimumab: the randomized CONCERTO trial. Ann Rheum Dis 2015; 74: 1037–1044.
7. Favalli EG, Bugatti S, Biggioggero M. Treatment comparison in rheumatoid arthritis: head-to-head trials and innovative study designs. Biomed Res Int 2014; 2014: 831603–831603.
8. Arnett FC, Edworthy SM, Bloch DA. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988; 31: 315–324.
9. Aletaha D, Neogi T, Silman AJ. 2010 Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62: 2569–2581.
10. Prevoo ML, van’t Hof MA, Kuper HH. Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. Arthritis Rheum 1995; 38: 44–48.
11. Smolen JS, Breedveld FC, Schiff MH. A simplified disease activity index for rheumatoid arthritis for use in clinical practice. Rheumatology (Oxford) 2003; 42: 244–257.
12. Bathon JM, Martin RW, Fleischmann RM. A comparison of etanercept and methotrexate in patients with early rheumatoid arthritis. N Engl J Med 2000; 343: 1586–1593.